PDCD1 and head and neck squamous cell carcinoma: In 2016, the US Food and Drug Administration (FDA) approved two PD-1 monoclonal antibodies, nivolumab and pembrolizumab, for the treatment of platinum-resistant recurrent metastatic HNSCC.